CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
As tumors outgrow their blood and nutrient supplies, or respond to treatments like chemotherapy and radiotherapy, individual ...
CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results